Clinical trial of icosapent ethyl finds 25 percent reduction in cardiovascular events among at-risk patients.
Deepak L. Bhatt, MD, MPH, Executive Director of Interventional Cardiovascular Program in the Heart & Vascular Center, presented results from the REDUCE-IT clinical trial, which tested whether icosapent ethyl, a highly purified form of a fish oil, could reduce the risk of cardiovascular events in at-risk patients who either had atherosclerosis, or diabetes plus at least one other cardiovascular risk factor along with elevated triglyceride levels, despite taking statins.
The REDUCE-IT trial showed that participants who took icosapent ethyl saw a 25 percent risk reduction in cardiovascular events and a 20 percent reduction in death due to cardiovascular causes, a result Dr. Bhatt described as “remarkable.”
“This may be the biggest development in cardiovascular secondary prevention since statins. The REDUCE-IT trial sets a new standard of care for these patients,” said Dr. Bhatt.
See the press release for more information about the REDUCE-IT clinical trial.
